LINAGLIPTIN
-
Lupin gets FDA tentative nod for Trijardy equivalent tablets
The approved tablets are generic equivalent of Trijardy XR Extended-Release tablets of Boehringer Ingelheim Pharmaceuticals, Inc. and the product will be manufactured at Lupin’s Pithampur facility in India.
-
Theon Pharmaceutical launches Linagliptin + Dapagliflozin + Metformin Hydrochloride (SR) for type 2 diabetes management for the first time in India
-
Pharmaceutical companies restrained from making diabetes drug
-
Boehringer Ingelheim obtains ad-interim injunctions against four domestic pharma cos over infringing diabetic drug
-
Zydus Cadila gets tentative nod from USFDA to market diabetes drug
-
Zydus Cadila gets tentative approval for generic diabetes drug
-
Cipla, Boehringer Ingelheim join hands to co-market 3 oral anti-diabetic drugs in India
-
Zydus Cadila gets tentative USFDA nod for diabetes drug
-
Lupin, Boehringer Ingelheim to co-market anti-diabetes drug linagliptin in India
Advertisement
Advertisement
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
